Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial
Trial registry name: CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas. Registration identification number: NCT02766270. URL for the registry: https://clinicaltrials.gov/study/NCT02766270?cond=NCT02766270&rank=1.
Authors
- Xiaoguang Qiu (ORCID: https://orcid.org/0000-0002-6806-9827)
- Jing Zhang (ORCID: https://orcid.org/0000-0001-7525-2075)
- Zhaoshi Bao (ORCID: https://orcid.org/0000-0003-4922-4470)
- Kaiwen Deng (ORCID: https://orcid.org/0009-0002-9517-2851)
- Li Chen (ORCID: https://orcid.org/0000-0003-2454-4849)
- Fei Liu (ORCID: https://orcid.org/0000-0001-8827-4409)
- Peng Wang (ORCID: https://orcid.org/0000-0002-5808-4265)
- Yin Ren
- Yanwei Liu (ORCID: https://orcid.org/0000-0002-4136-3954)
- Feng Jin (ORCID: https://orcid.org/0000-0002-4896-9713)
Institutions
- Capital Medical University (CN)
- Beijing Tian Tan Hospital (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Beijing Institute of Neurosurgery (CN)
Publication Details
- Journal
- Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/cncr.70171
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00